A veterinary oncologist discusses his lecture on recent lymphoma findings

In an interview with dvm360 at the Fetch dvm360 conference in Atlantic City, New Jersey, Philip Bergman, DVM, MS, PhD, DACVIM, discussed his lecture “Lymphoma – What’s New?” Bergman explained that the session focuses on what recent literature identifies as risk factors, new therapies, and rescue protocols for lymphoma in canine patients. In his lecture, Bergman also talks about the novel drug Laverdia-CA1 (verdinexor tablets)—the first oral tablet FDA-conditionally approved to treat lymphoma in dogs.¹

Below is the interview transcript

Philip Bergman, DVM, MS, PhD, DACVIM: In that lecture, what I try to do is stay very, very clinically relevant. I do everything I can to not get very molecular. I know a lot of people worry when they see the PhD or piled higher and deeper degree that, ‘Oh my god. He's going to talk about molecular this, molecular that’—[the lecture is] nothing about that at all.

It's really sitting down and talking about some of the newer literature related to, what are some of the risk aspects with that disease, what are some of the new therapies that are coming out? And also, spend a little time talking about a new drug called Laverdia-CA1, which is a drug that I think is very targeted for the general practice setting, that is an easy twice a week oral medication. So pretty easy for clients, pretty easy on pets. We do see occasional side effects, but most of the time it's self-limiting.

And then we spend a lot of time in the lecture talking about what are some of the rescue protocols, because that's one of the most common questions that I get asked of the primary care doctors that are around me.

Reference

1. Laverdia-CA1 (verdinexor tablets). Dechra. Accessed November 22, 2024. https://www.dechra-us.com/our-products/us/companion-animal/dog/prescription/laverdia-ca1-verdinexor-tablets